Tobira Therapeutics (TBRA) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Tobira Therapeutics Reports First Quarter 2016 Financial and Business Results
May 9, 2016 4:05 PM EDTSOUTH SAN FRANCISCO, Calif., May 9, 2016 /PRNewswire/ --Â Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today reported business highlights and financial results for the three months ended March 31, 2016.
"We had a great start to 2016 and we are on track to report the year-one primary endpoint of CENTAUR, our Phase 2b study of cenicriviroc in non-alcoholic steatohepatitis, in the third quarter. Last week, we announced encouraging interim results from the ORION study. In... More
